Van Hulzen Asset Management LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Van Hulzen Asset Management LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,161 shares of the company’s stock after purchasing an additional 49 shares during the quarter. Van Hulzen Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,957,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Tidemark LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth about $29,000. Core Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the period. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $32,000. LGT Financial Advisors LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $36,000. Finally, Frank Rimerman Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $37,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 15,022 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $882.47, for a total transaction of $13,256,464.34. Following the sale, the insider now owns 97,778,788 shares of the company’s stock, valued at $86,286,847,046.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 661,900 shares of company stock worth $604,721,602. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 0.6 %

NYSE:LLY opened at $908.39 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The company has a 50-day moving average of $895.85 and a 200 day moving average of $829.55. The firm has a market cap of $863.36 billion, a PE ratio of 133.78, a price-to-earnings-growth ratio of 2.73 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts anticipate that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on LLY shares. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Barclays increased their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Bank of America raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $961.76.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.